Please insert pages 1-17 of the accompanying sequence listing following page 109 of the application, which describes the abstract of the invention, and renumber the sequence listing pages 110-126 accordingly.

On page 1, line 2, immediately after the title "Diagnostics and Therapeutics for Restenosis,," please insert the following paragraph:

B1

Related U.S. Applications

This application is a continuation-in-part of U.S. Application Serial Number 09/431,352 filed November 1, 1999, which application is hereby incorporated by reference.

On page 88, lines 4-10 please replace the paragraph appearing at lines 4-10 with the following paragraph:

B2

Results: Typing of additional numbers of individuals is required to bring the results to significance, but preliminary results indicate that allele 1 of the 4845, -511, +3954 and VNTR markers in the IL-1RN gene will be over-represented in restenosis. It is predicted that individuals with at least one copy of allele 1 from one of the above markers are more likely to have restenosis than those who are negative for allele 1. Individuals who are homozygous for any of these alleles, or have allele 1 from more than one marker are estimated to have even higher risk for restenosis.

IN THE CLAIMS

Pursuant to 37 C.F.R. § 1.121(c)(1-3), please replace claims 1 and 5 with claims 1 as set forth below:

B3

1. **(Amended)** A method for determining whether a subject has or is predisposed to developing restenosis, comprising detecting a restenosis associated IL-1 allele in a nucleic acid sample from the subject, wherein detection of the restenosis allele indicates that the subject has or is predisposed to the development of restenosis.